Tempus AI Goes Public: Raising $410.7M for Precision Medicine with a Market Valuation of $6B

Chicago, Illinois United States of America
Founder Eric Lefkofsky holds 65% of the shareholder voting power after the IPO. Morgan Stanley, JPMorgan Chase & Co., Allen & Company served as lead underwriters for Tempus AI's offering.
Tempus AI aims to make laboratory tests more accurate, tailored, and personal using AI technology.
Tempus AI sells genomics diagnostics tests across various areas including neuropsychiatry, radiology, and cardiology.
Tempus AI's platform connects laboratory results to clinical data and has been used by over 7,000 physicians across hundreds of provider networks.
Tempus AI went public on June 14, 2024, raising $410.7 million and achieving a market valuation of $6 billion.
Tempus AI Goes Public: Raising $410.7M for Precision Medicine with a Market Valuation of $6B

Tempus AI, a technology company that uses artificial intelligence (AI) to process medical data and create 'intelligent diagnostics' for precision medicine, went public on June 14, 2024. The company priced its initial public offering (IPO) at $37 per share after initially targeting a range of $35 to $37. With this offering, Tempus AI raised approximately $410.7 million and achieved a market valuation of around $6 billion.

Tempus AI's platform connects laboratory results to a patient's clinical data and has been used by over 7,000 physicians across hundreds of provider networks. The company had revenues of $532 million in 2023 but reported a net loss of $214 million. Tempus AI aims to make laboratory tests more accurate, tailored, and personal using AI technology.

The company's founder and CEO, Eric Lefkofsky, holds 65% of the shareholder voting power after the IPO. Morgan Stanley, JPMorgan Chase & Co., Allen & Company served as lead underwriters for Tempus AI's offering. The shares are expected to begin trading on the Nasdaq Global Select Market under the symbol TEM.

Tempus AI sells genomics diagnostics tests across various areas including neuropsychiatry, radiology, and cardiology. The company is applying artificial intelligence and data analysis to healthcare with a focus on precision medicine and understanding tumors at the molecular level.

The IPO comes after SoftBank Group invested in Tempus AI. Lefkofsky co-founded Groupon before starting Tempus AI.


Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image

Confidence

95%

Doubts
  • Is the revenue figure of $532 million for 2023 accurate?
  • What is the exact net loss reported by Tempus AI in 2023?

Sources

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Google-backed Tempus AI closes first day of trading up 9% in Nasdaq stock market debut

CNBC News Riley de Friday, 14 June 2024 16:01
  • Unique Points
    • Tempus AI went public on Friday and rose up to 15% in its Nasdaq Stock Market debut.
    • ,
    • Tempus AI aims to make laboratory tests more accurate, tailored, and personal using artificial intelligence (AI).
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

98%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Tempus AI Raises $410.7 Million in IPO, at the Top of Range

Bloomberg News Now Amy Or Sunday, 16 June 2024 03:35
  • Unique Points
    • Tempus AI sold 11.1 million shares for $37 each
    • Tempus AI priced its IPO at the top of the marketed range
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Medical Data Firm Tempus AI Raises $410.7 Million in IPO

Yahoo Finance Amy Or Sunday, 16 June 2024 03:36
  • Unique Points
    • Tempus AI connects laboratory results to a patient’s clinical data and has been used by over 7,000 physicians across hundreds of provider networks.
    • Tempus AI had a net loss of $214 million on revenue of $532 million in 2023.
    • Eric Lefkofsky is the founder and CEO of Tempus AI and will have 65% of the shareholder voting power after the IPO.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

98%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Tempus AI prices US IPO at over $6 billion valuation

Entertainment Variety Tv Site: https://www.yahoo.com/entertainment/tv-site/ Unknown Reuters Sunday, 16 June 2024 03:36
  • Unique Points
    • Tempus AI sells genomics diagnostics tests across various areas including neuropsychiatry, radiology and cardiology.
    • Tempus AI is applying artificial intelligence and data analysis to healthcare, focusing on precision medicine and understanding tumors at the molecular level.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication